1. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Issue 10336 (30th April 2022) Authors: Fizazi, Karim; Foulon, Stéphanie; Carles, Joan; Roubaud, Guilhem; McDermott, Ray; Fléchon, Aude; Tombal, Bertrand; Supiot, Stéphane; Berthold, Dominik; Ronchin, Philippe; Kacso, Gabriel; Gravis, Gwenaëlle; Calabro, Fabio; Berdah, Jean-François; Hasbini, Ali; Silva, Marlon; Thiery-Vuillemin, Antoi... Journal: Lancet Issue: Volume 399:Issue 10336(2022) Page Start: 1695 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗